Bringing a medicine or medical device to the UK market involves more than regulatory approval and scientific accuracy. Product information, labelling, patient information and technical documentation must communicate safety and usage information clearly and consistently.
This makes MHRA translation requirements an important consideration for pharmaceutical manufacturers, medical-device companies, biotechnology businesses, CROs and regulatory teams working with UK healthcare products.
However, there is no single translation rule that applies to every pharmaceutical or medical-device document. Requirements can depend on the product, document type, regulatory pathway, intended audience and UK market involved.
This guide explains the key considerations for pharmaceutical and medical document translation in the UK, including Patient Information Leaflets (PILs), Summary of Product Characteristics (SmPCs), medical-device Instructions for Use (IFUs), labelling, packaging, regulatory documents and certified translations.
Important: Regulatory requirements can change. Always verify the requirements applicable to your specific product, document and market against current MHRA and UK regulatory guidance before submitting or publishing translated content.
What Are the MHRA Translation Requirements in the UK?
MHRA translation requirements refer broadly to the need for regulated healthcare information to be accurate, clear, consistent and appropriate for its intended audience.
For medicines, this can include product information such as Patient Information Leaflets (PILs), labelling and other information associated with a marketing authorisation. The MHRA provides guidance covering medicines packaging, labelling and patient information leaflets.
For medical devices, requirements depend on the applicable UK market and regulatory framework. The MHRA's current guidance distinguishes between Great Britain (England, Scotland and Wales) and Northern Ireland, where different regulatory rules can apply.
A compliant translation workflow should therefore consider:
The specific healthcare product
The applicable UK regulatory pathway
The target audience
The intended market
Required product information
Medical and technical terminology
Safety warnings and instructions
Units, numbers and measurements
Document versions and revisions
Formatting and artwork requirements
The objective is not simply to translate words from one language to another. The translated document must preserve the meaning and safety information of the approved source material.
MHRA Translation Requirements at a Glance
Who Needs Pharmaceutical or Medical Document Translation?
Organisations developing, manufacturing, distributing or registering healthcare products may need specialist translation support.
This can include:
Pharmaceutical manufacturers
Medical-device manufacturers
Biotechnology companies
Contract research organisations (CROs)
Clinical research teams
Healthcare organisations
Regulatory affairs teams
Multinational pharmaceutical companies
Medical technology companies
Healthcare distributors
Translation requirements vary according to the product and regulatory context. A specialist pharmaceutical translation UK provider can help organisations manage terminology, document consistency, and quality across regulated content.
Which Pharmaceutical Documents Need Translation?
The documents requiring translation depend on the regulatory pathway and intended use of the material. Pharmaceutical documentation may include:
For medicines, the MHRA regulates packaging, labelling and Patient Information Leaflets. Its current guidance states that medicines must include a PIL where the label does not contain all the necessary information.
The MHRA also provides a medicines product-information service covering PILs, summaries of product characteristics and public assessment reports.
Do Patient Information Leaflets (PILs) Need Translation?
Where a translated Patient Information Leaflet is required for the applicable regulatory or market context, the translation needs to accurately communicate the approved medicine information while remaining clear and understandable for patients.
A PIL may contain important information about:
What the medicine is used for
How to take or use it
Dosage
Warnings and precautions
Possible side effects
Contraindications
Storage conditions
Interactions
What to do in specific circumstances
The MHRA's best-practice guidance highlights the importance of clear and accessible patient information so that patients can make informed decisions about the safe and effective use of their medicines.
What Should a PIL Translation Preserve?
A high-quality PIL translation should preserve:
Medical meaning
Dosage information
Safety warnings
Contraindications
Side-effect information
Product terminology
Numerical information
Units of measurement
Storage instructions
Version information
References to other product information
The translation should not introduce a new medical meaning or unintentionally change the instructions provided in the approved source content.
Do Medical Device IFUs Need to Be Translated for the UK?
Medical-device language requirements depend on the applicable UK market and regulatory framework.
For Great Britain, the applicable framework is based on the UK Medical Devices Regulations 2002, as amended. Northern Ireland has different arrangements under the applicable Northern Ireland medical-device framework. The MHRA specifically separates its guidance for Great Britain, Northern Ireland and the EU.
An IFU may contain information about:
Device installation
Operation
Intended use
Maintenance
Cleaning
Storage
Safety warnings
Contraindications
Technical specifications
Troubleshooting
Disposal
User precautions
Because users may rely directly on an IFU when operating a medical device, translation errors can affect the safe and intended use of the product.
Where electronic IFUs are used, applicable UK requirements can also address how users access the instructions, identifying the appropriate version and providing information about available languages.
What Are the Language Requirements for Medical Devices in Great Britain?
Great Britain comprises England, Scotland and Wales. Medical-device requirements for Great Britain are based on the UK regulatory framework, while Northern Ireland follows different arrangements.
Manufacturers should therefore avoid treating “UK medical-device translation requirements” as one universal set of rules.
Before translating a medical-device document, establish:
Where the device will be placed on the market.
Which regulatory framework applies.
Who will use the device.
Which information must accompany the device.
Which language requirements apply.
Whether the document is patient-facing, professional-facing or technical.
Whether the document is printed or electronic.
This approach reduces the risk of applying the wrong language or documentation requirements to a particular market.
Great Britain vs Northern Ireland: Why the Distinction Matters
One of the most important considerations when planning UK medical-device translation is the difference between Great Britain and Northern Ireland.
The MHRA states that different rules apply to Northern Ireland and Great Britain for medical devices. Manufacturers should therefore confirm the relevant framework before preparing translated IFUs, labels or other device documentation.
Does the MHRA Require Certified Translations?
Not every pharmaceutical or medical-device document automatically requires a certified translation.
Whether certification is required depends on factors such as:
The type of document
The regulatory procedure
The receiving authority
The purpose of the translation
Any specific submission instructions
Legal or contractual requirements
A professional medical translation and a certified translation are not necessarily the same thing.
Professional Medical Translation
A specialist medical translation focuses on:
Medical terminology
Technical accuracy
Regulatory terminology
Consistency
Patient safety
Linguistic quality
Certified Translation
A certified translation involves a formal certification or declaration of accuracy where certification is required by the relevant authority or procedure.
Therefore, companies should determine whether certification, professional review, notarisation or another form of verification is actually required before commissioning the translation.
What Is the Pharmaceutical Translation and Quality Assurance Process?
Regulated medical translation should follow a documented and repeatable workflow.
Step 1: Identify the Regulatory Pathway
Determine whether the document relates to a medicine, medical device, clinical research activity or another regulated healthcare product.
Step 2: Identify the Target Market
Confirm whether the document is intended for Great Britain, Northern Ireland or another market.
Step 3: Identify the Required Documents
Create a translation inventory covering relevant PILs, SmPCs, IFUs, labels, packaging and supporting documentation.
Step 4: Establish Terminology
Create or review approved glossaries and product-specific terminology before translation begins.
Step 5: Specialist Translation
Use translators with appropriate pharmaceutical, medical-device or healthcare expertise.
Step 6: Independent Review
Have the translated content reviewed for terminology, accuracy, completeness and consistency.
Step 7: Linguistic Quality Assurance
Check:
Numbers
Dosages
Units
Warnings
Headings
References
Product names
Terminology
Formatting
Version numbers
Step 8: Artwork and Formatting Validation
For packaging, labels and IFUs, verify that the translated text fits correctly and remains readable.
Step 9: Final Approval and Version Control
Confirm that the final translation corresponds to the correct source version and that subsequent changes are tracked consistently.
10 Common Pharmaceutical and Medical Translation Mistakes
Poor translation can create unnecessary review cycles, inconsistencies, and potential compliance risks.
Common mistakes include:
Literal translation of medical terminology
Inconsistent terminology between documents
Incorrect dosage or numerical information
Incorrect units of measurement
Changes to safety warnings during translation
Use of outdated source documents
Inconsistent product names
Formatting errors in packaging artwork
Failure to update revised safety information
Using translators without relevant pharmaceutical or medical expertise
A structured review process can help identify these issues before translated documents are used or submitted.
How Do You Choose a Pharmaceutical Translation Partner?
The right pharmaceutical translation partner should offer more than general language skills.
Look for a provider with:
Native-language linguists
Pharmaceutical or medical-device expertise
Regulatory translation experience
Independent review processes
Terminology management
Translation memory capabilities
Confidentiality procedures
Quality-assurance workflows
Document formatting capabilities
Version-control processes
Experience with regulated healthcare documentation
For organisations managing large volumes of regulatory content, consistent terminology becomes particularly important. The same product terminology may appear across PILs, SmPCs, labels, packaging, clinical documentation, and other materials.
MHRA Translation Compliance Checklist
Before finalising a pharmaceutical or medical-device translation, check:
Correct regulatory pathway identified
Correct UK market identified
Applicable language requirements confirmed
Current approved source document used
Medical terminology reviewed
Dosage information checked
Numbers and units checked
Safety warnings reviewed
Contraindications checked
Product names verified
Approved terminology maintained
Independent linguistic review completed
Formatting and artwork validated
Document version confirmed
Regulatory updates incorporated
Final approval completed
This checklist should be treated as a quality-control aid rather than a substitute for product-specific regulatory advice.
Are MHRA and UKCA Translation Requirements the Same?
No. MHRA requirements and UKCA requirements are not interchangeable.
The MHRA is responsible for regulating medicines and medical devices in the UK. UKCA, meanwhile, is a conformity-marking framework relevant to certain products.
For medical devices, manufacturers need to consider the applicable regulatory framework, conformity assessment route, marking requirements, registration requirements and information supplied with the device.
The exact requirements depend on the product and market. Current MHRA guidance separates the rules applicable to Great Britain, Northern Ireland and the EU.
Therefore, companies should not assume that meeting a UKCA-related requirement automatically answers every translation or language requirement for their medical-device documentation.
Why Accuracy Matters in Pharmaceutical and Medical Translation?
Translation quality is particularly important when documents communicate information that can affect how a medicine or medical device is used.
A translation error involving a dosage, warning, contraindication, storage instruction or operating procedure can change the intended meaning of the source content.
For this reason, regulated healthcare translation should combine:
Linguistic accuracy + Medical expertise + Regulatory awareness + Quality assurance
This is especially important for patient-facing documents, where information needs to be both medically accurate and understandable.
The MHRA's current work on improving patient information also emphasizes the importance of clear, accessible and trusted information about medicines.
Conclusion: Get Pharmaceutical and Medical Translations Right the First Time
MHRA translation requirements are not simply about converting healthcare documents from one language to another. They involve maintaining the accuracy, clarity, consistency and intended meaning of regulated medical information.
For pharmaceutical products, important documentation can include Patient Information Leaflets, labelling, packaging and product information. For medical devices, manufacturers must consider the applicable requirements for the relevant UK market, particularly because Great Britain and Northern Ireland operate under different regulatory arrangements.
A specialist translation workflow can help organisations manage:
Pharmaceutical translations
Medical-device translations
Patient Information Leaflets
SmPCs
Instructions for Use
Regulatory documents
Labelling and packaging
Clinical documentation
Safety information
At MyTranscriptionPlace, specialist linguists, terminology management and quality-control processes can help healthcare organisations manage complex pharmaceutical and medical translation requirements while maintaining consistency across regulated documentation.
If you are preparing pharmaceutical, medical-device or regulatory documentation for the UK market, work with a translation partner that understands both medical terminology and the quality requirements of regulated healthcare content.
Regulatory Disclaimer
This article provides general information about pharmaceutical and medical-device translation considerations in the UK. It is not legal or regulatory advice. Requirements can vary according to the product, document, regulatory pathway and market and may change over time. Always consult the current MHRA, UK government and applicable regulatory guidance for your specific situation.
Our Best Translation Services
English to Indonesian Translation | English to Spanish Translation | English to Italian Translation | English to Russian Translation | English to Danish Translation | English to Vietnamese Translation | English to Japanese Translation | English to Finnish Translation | English to Dutch Translation | English to Arabic Translation | English to Norwegian Translation | English to Greek Translation.
Frequently Asked Questions About MHRA Translation Requirements
1. What are the MHRA translation requirements in the UK?
MHRA translation requirements depend on the product, document, regulatory pathway and intended market. Pharmaceutical and medical-device information should be accurate, consistent and appropriate for its intended audience. Requirements can apply to product information, labelling, PILs, IFUs and other regulated documentation.2. Does the MHRA require certified translations?
Not every document requires a certified translation. Certification requirements depend on the specific document, regulatory procedure, receiving authority and intended use. Companies should confirm whether certification or another form of verification is required before submitting translated documents.3. Do pharmaceutical documents need to be translated for the UK?
Translation requirements depend on the specific document and regulatory context. Pharmaceutical product information may include PILs, labelling, SmPCs and other regulatory materials. Where translation is required, the content should accurately communicate the approved medical and safety information.4. Do medical-device IFUs need to be translated for the UK?
Medical-device IFU requirements depend on the applicable UK market and regulatory framework. Great Britain and Northern Ireland have different medical-device regulatory arrangements, so manufacturers should confirm the requirements applicable to their specific device and market.5. What language is required for medical devices in Great Britain?
Manufacturers should follow the language requirements applicable to the specific medical device and regulatory pathway in Great Britain. Great Britain consists of England, Scotland and Wales and operates under its UK medical-device framework.6. Does the MHRA approve translated Patient Information Leaflets?
The MHRA regulates medicines information, including packaging, labelling and Patient Information Leaflets. A translated PIL should accurately reflect the applicable approved product information and meet relevant requirements for clarity and presentation.7. Which pharmaceutical documents commonly require translation?
Depending on the regulatory and commercial context, documents may include Patient Information Leaflets, SmPCs, product labels, packaging artwork, clinical documents, safety information, regulatory submissions and manufacturing documentation.8. What is the difference between MHRA and UKCA requirements?
MHRA requirements relate to the regulation of medicines and medical devices, while UKCA is a conformity-marking framework applicable to certain products. They address different aspects of regulatory compliance and should not be treated as interchangeable.9. Are medical-device translation requirements the same in Great Britain and Northern Ireland?
No. Different medical-device regulatory arrangements apply in Great Britain and Northern Ireland. Manufacturers should identify the applicable market and regulatory framework before preparing translated device documentation.10. What qualifications should a pharmaceutical translator have?
A pharmaceutical translator should have strong language skills combined with relevant knowledge of pharmaceutical terminology, medical concepts and regulated healthcare documentation. Experience with product information, regulatory documents and quality-assurance processes is also valuable.11. How can pharmaceutical companies maintain terminology consistency?
Companies can use approved glossaries, terminology databases and translation memories together with specialist review. Maintaining a controlled terminology set helps keep product names, medical terms, warnings and technical language consistent across PILs, SmPCs, labels, IFUs and other documents.12. How should translated pharmaceutical documents be quality checked?
Quality checks should cover medical terminology, meaning, numbers, dosage information, units, warnings, product names, formatting, document versions and consistency with the approved source. Independent linguistic review and final quality assurance can provide an additional layer of control.
Nishi Singh
(Content Writer & SEO Manager)
She is an SEO Manager with over 8 years of experience in marketing and content creation. She specializes in SEO, content strategy, and paid advertisements, helping website owners across SaaS, B2B businesses, and e-commerce platforms achieve measurable growth. With a strong focus on driving organic traffic and crafting impactful content, Nishi has established herself as a trusted expert in the digital marketing space. When she's not optimizing websites, she channels her energy into marathon running, embracing challenges both on and off the track.
